• Pediatric Hematologic Malignancies Clinical Trials

    Our scientists and physicians conduct extensive laboratory and clinical research to identify new treatments and improve therapies for children with hematologic malignancies. Our team’s achievements include:

    • Improving leukemia cure rates and reducing chemotherapy-associated side effects
    • Developing treatment protocols that offer the best published cure rates for children with acute lymphoblastic leukemia
    • Conducting innovative clinical trials of new, promising agents in children with relapsed and refractory leukemia and lymphoma
    • Reducing the risk of late effects of treatment (learning disabilities, heart dysfunction and bone problems) in leukemia survivors
    • Discovering unique genetic mutations associated with histiocytosis and working to develop treatments based on this discovery

    We lead an internationally recognized clinical trials consortium for children and adolescents with newly diagnosed acute lymphoblastic leukemia – the DFCI ALL Consortium – consisting of 9 institutions in the United States and Canada. We are a founding member of a small national consortium of leading medical centers that investigate new treatments for children with Hodgkin lymphoma, including innovative drug combinations (and reduced exposure to radiation) that deliver results with fewer long-term complications. In addition, we participate in clinical trials conducted by the Histiocyte Society for patients with Langerhans Cell Histiocytosis.

    To inquire about clinical trials, email us at clinicaltrials@danafarberbostonchildrens.org and read our clinical trial FAQ for answers to general questions.

    Featured Trials

    To learn more about how Everolimus works in combination with other drugs which are commonly used to treat relapsed acute lymphoblastic leukemia (prednisone, vincristine, PEG-asparaginase, and doxorubicin). The main goal of the study is to evaluate the side effects of this treatment combination in order to determine a safe dose of Everolimus which can be given with these other 4 drugs. PI: Lewis B. Silverman, MD

    Dr. Lewis Silverman Learn whether the side effects and drug levels of SC-PEG given in the vein every 3 weeks are similar to Oncaspar given into the vein every 2 weeks. The study will also help to determine whether changing treatment for ALL patients with high levels of minimal residual disease after one month of chemotherapy may improve cure rates. PI: Lewis B. Silverman, MD


    Search Trials by Condition

    Search trials by condition using the links below, or download a summary of all current trials at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.